G Protein Mutations in Pituitary Tumors: a Study on Turkish Patients

Overview

Journal Pituitary

Specialty Endocrinology

Date 2004 Jan 2

PMID 14703016

Citations 7

Authors

Beki Kan

Christopher Esapa

Tammam Sipahi

Cevdet Nacar

Fahir Ozer

Nur Buyru Sayhan

Mehmet Yasar Kaynar

Ali Cetin Sarioglu

Philip Edward Harris

Affiliations

Soon will be listed here.

Abstract

Activating mutations of the G proteins, Gsalpha (gsp) and Gi2alpha (gip) have been reported in subsets of pituitary tumors. The objective of the study was to assess the frequency of gsp and gip mutations in pituitary tumors from Turkish patients and to investigate the possibility of mutations of protein kinase A catalytic subunit (PKAC) that activates the downstream effectors of adenylyl cyclase. PCR-amplified genomic DNA was analyzed for the presence of mutations in codons 201 and 227 of Gsalpha, codon 179 and 205 of Gi2alpha and codon 196 of PKAC, by single strand conformation polymorphism analysis, allele-specific oligonucleotide hybridization and DNA sequencing. Twenty-two patients from Turkey, 15 females and 7 males were investigated; 7 somatotroph adenomas, 7 clinically non-functioning tumors, 7 prolactinomas and 1 corticotroph adenoma. G protein mutations were identified in 6 of 22 (27.3%) pituitary tumors. Four tumors (3/7 somatotroph adenomas, 43%, 1/7 clinically non-functioning tumor) demonstrated gsp mutations at codon 201 arginine to cysteine and one recurrent somatotroph adenoma demonstrated a mutation of the Gi2alpha gene at codon 193 lysine to arginine. One tumor exhibited a C to T variation in the intervening sequence between codons 179 and 205 of the Gi2alpha gene. No mutations at codon 227 of Gsalpha, codons 179 and 205 of Gi2alpha and codon 196 of the PKAC gene were identified.

Citing Articles

The curious case of Gαs gain-of-function in neoplasia.

Innamorati G, Wilkie T, Kantheti H, Valenti M, Dalle Carbonare L, Giacomello L BMC Cancer. 2018; 18(1):293.

PMID: 29544460 PMC: 5856294. DOI: 10.1186/s12885-018-4133-z.

Mutation analysis of inhibitory guanine nucleotide binding protein alpha (GNAI) loci in young and familial pituitary adenomas.

Demir H, Donner I, Kivipelto L, Kuismin O, Schalin-Jantti C, De Menis E PLoS One. 2014; 9(10):e109897.

PMID: 25291362 PMC: 4188600. DOI: 10.1371/journal.pone.0109897.

Hope for GWAS: relevant risk genes uncovered from GWAS statistical noise.

Correia C, Diekmann Y, Vicente A, Pereira-Leal J Int J Mol Sci. 2014; 15(10):17601-21.

PMID: 25268625 PMC: 4227180. DOI: 10.3390/ijms151017601.

Non-functioning pituitary adenomas infrequently harbor G-protein gene mutations.

Ruggeri R, Santarpia L, Curto L, Torre M, Galatioto M, Galatioto S J Endocrinol Invest. 2009; 31(11):946-9.

PMID: 19169048 DOI: 10.1007/BF03345630.

Prevalence of gsp oncogene in somatotropinomas and clinically non-functioning pituitary adenomas: our experience.

Fernandes Taboada G, Tabet A, Naves L, Pires de Carvalho D, Gadelha M Pituitary. 2008; 12(3):165-9.

PMID: 18642089 DOI: 10.1007/s11102-008-0136-0.

References

Clementi E, Malgaretti N, Meldolesi J, Taramelli R . A new constitutively activating mutation of the Gs protein alpha subunit-gsp oncogene is found in human pituitary tumours. Oncogene. 1990; 5(7):1059-61. View

Barlier A, Gunz G, Zamora A, Jaquet P, Enjalbert A . Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity. J Clin Endocrinol Metab. 1999; 84(8):2759-65. DOI: 10.1210/jcem.84.8.5919. View

OSullivan C, Barton C, Staddon S, Brown C, Lemoine N . Activating point mutations of the gsp oncogene in human thyroid adenomas. Mol Carcinog. 1991; 4(5):345-9. DOI: 10.1002/mc.2940040503. View

Hepler J, GILMAN A . G proteins. Trends Biochem Sci. 1992; 17(10):383-7. DOI: 10.1016/0968-0004(92)90005-t. View

Yoshimoto K, Iwahana H, Fukuda A, Sano T, Itakura M . Rare mutations of the Gs alpha subunit gene in human endocrine tumors. Mutation detection by polymerase chain reaction-primer-introduced restriction analysis. Cancer. 1993; 72(4):1386-93. DOI: 10.1002/1097-0142(19930815)72:4<1386::aid-cncr2820720439>3.0.co;2-j. View

Drews R, Gravel R, Collu R . Identification of G protein alpha subunit mutations in human growth hormone (GH)- and GH/prolactin-secreting pituitary tumors by single-strand conformation polymorphism (SSCP) analysis. Mol Cell Endocrinol. 1992; 87(1-3):125-9. DOI: 10.1016/0303-7207(92)90240-7. View

Gonzalez G, Montminy M . Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell. 1989; 59(4):675-80. DOI: 10.1016/0092-8674(89)90013-5. View

Boggild M, Jenkinson S, Pistorello M, Boscaro M, Scanarini M, McTernan P . Molecular genetic studies of sporadic pituitary tumors. J Clin Endocrinol Metab. 1994; 78(2):387-92. DOI: 10.1210/jcem.78.2.8106627. View

Vallar L . Oncogenic role of heterotrimeric G proteins. Cancer Surv. 1996; 27:325-38. View

10.

Landis C, Masters S, Spada A, Pace A, Bourne H, Vallar L . GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature. 1989; 340(6236):692-6. DOI: 10.1038/340692a0. View

11.

Faglia G, Arosio M, Spada A . GS protein mutations and pituitary tumors: functional correlates and possible therapeutic implications. Metabolism. 1996; 45(8 Suppl 1):117-9. DOI: 10.1016/s0026-0495(96)90103-1. View

12.

Ballare E, Mantovani S, Lania A, Di Blasio A, Vallar L, Spada A . Activating mutations of the Gs alpha gene are associated with low levels of Gs alpha protein in growth hormone-secreting tumors. J Clin Endocrinol Metab. 1998; 83(12):4386-90. DOI: 10.1210/jcem.83.12.5354. View

13.

Adams E, Brockmeier S, Friedmann E, Roth M, Buchfelder M, Fahlbusch R . Clinical and biochemical characteristics of acromegalic patients harboring gsp-positive and gsp-negative pituitary tumors. Neurosurgery. 1993; 33(2):198-203; discussion 203. DOI: 10.1227/00006123-199308000-00003. View

14.

Dhanasekaran N, Heasley L, Johnson G . G protein-coupled receptor systems involved in cell growth and oncogenesis. Endocr Rev. 1995; 16(3):259-70. DOI: 10.1210/edrv-16-3-259. View

15.

Yang I, Park S, Ryu M, Woo J, Kim S, Kim J . Characteristics of gsp-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients. Eur J Endocrinol. 1996; 134(6):720-6. DOI: 10.1530/eje.0.1340720. View

16.

Esapa C, Harris P . Mutation analysis of protein kinase A catalytic subunit in thyroid adenomas and pituitary tumours. Eur J Endocrinol. 1999; 141(4):409-12. DOI: 10.1530/eje.0.1410409. View

17.

Lyons J, Landis C, Harsh G, Vallar L, Grunewald K, Feichtinger H . Two G protein oncogenes in human endocrine tumors. Science. 1990; 249(4969):655-9. DOI: 10.1126/science.2116665. View

18.

Tordjman K, Stern N, Ouaknine G, Yossiphov Y, Razon N, Nordenskjold M . Activating mutations of the Gs alpha-gene in nonfunctioning pituitary tumors. J Clin Endocrinol Metab. 1993; 77(3):765-9. DOI: 10.1210/jcem.77.3.8396579. View

19.

Orellana S, McKnight G . Mutations in the catalytic subunit of cAMP-dependent protein kinase result in unregulated biological activity. Proc Natl Acad Sci U S A. 1992; 89(10):4726-30. PMC: 49156. DOI: 10.1073/pnas.89.10.4726. View

20.

Vallar L, Spada A, Giannattasio G . Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature. 1987; 330(6148):566-8. DOI: 10.1038/330566a0. View